Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mediwound ( (MDWD) ) has issued an update.
On August 14, 2025, MediWound Ltd. announced its financial results for the second quarter of 2025, reporting a 43% increase in revenue from the prior quarter, reaching $5.7 million. The company highlighted ongoing patient enrollment in its VALUE Phase III trial for EscharEx, strategic collaborations with Essity and Convatec, and manufacturing expansion for NexoBrid, which is expected to reach full operational capacity by the end of 2025. Despite a net loss of $13.3 million, MediWound’s financial performance showed improved gross profit margins and increased R&D investments, reflecting confidence in its long-term strategy.
The most recent analyst rating on (MDWD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
Mediwound’s overall stock score is driven by financial challenges and a lack of positive valuation metrics. While technical analysis shows neutral trends, the potential for future growth from clinical trials and strategic initiatives provides some optimism.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics for tissue repair, focusing on products like EscharEx and NexoBrid for wound care and tissue healing. The company collaborates with leading global wound care companies and is expanding its manufacturing capabilities to meet growing demand.
Average Trading Volume: 63,097
Technical Sentiment Signal: Buy
Current Market Cap: $202.9M
For an in-depth examination of MDWD stock, go to TipRanks’ Overview page.